European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)

View source ↗

Summary

EMA recommends updating the product information for Tysabri to reflect risks of progressive multifocal leukoencephalopathy (PML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multifocal Leukoencephalopathy

Drugs mentioned

• Tysabri (Natalizumab)